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Abstract
Recent findings have identified competing endogenous RNAs (ceRNAs) as the drivers in
many disease conditions, including cancers. The ceRNAs indirectly regulate each other by
reducing the amount of microRNAs (miRNAs) available to target messenger RNAs
(mRNAs). The ceRNA interactions mediated by miRNAs are modulated by a titration mech-
anism, i.e. large changes in the ceRNA expression levels either overcome, or relieve, the
miRNA repression on competing RNAs; similarly, a very large miRNA overexpression may
abolish competition. The ceRNAs are also called miRNA “decoys” or miRNA “sponges” and
encompass different RNAs competing with each other to attract miRNAs for interactions:
mRNA, long non-coding RNAs (lncRNAs), pseudogenes, or circular RNAs. Recently, we
developed a computational method for identifying ceRNA-ceRNA interactions in breast inva-
sive carcinoma. We were interested in unveiling which lncRNAs could exert the ceRNA
activity. We found a drastic rewiring in the cross-talks between ceRNAs from the physiologi-
cal to the pathological condition. The main actor of this dysregulated lncRNA-associated
ceRNA network was the lncRNA PVT1, which revealed a net biding preference towards the
miR-200 family members in normal breast tissues. Despite its up-regulation in breast cancer
tissues, mimicked by the miR-200 family members, PVT1 stops working as ceRNA in the
cancerous state. The specific conditions required for a ceRNA landscape to occur are still
far from being determined. Here, we emphasized the importance of the relative concentra-
tion of the ceRNAs, and their related miRNAs. In particular, we focused on the withdrawal in
breast cancer tissues of the PVT1 ceRNA activity and performed a gene expression and
sequence analysis of its multiple isoforms. We found that the PVT1 isoform harbouring the
binding site for a representative miRNA of the miR-200 family shows a drastic decrease in
its relative concentration with respect to the miRNA abundance in breast cancer tissues,
providing a plausibility argument to the breakdown of the sponge program orchestrated by
the oncogene PVT1.
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Introduction
The last years have been marked by an increasing widespread interest in non-coding RNAs,
emerging as key regulators of many cellular processes in both physiological and pathological
states [1–4]. This class of RNA species appears really heterogeneous, including the intensively
studied microRNAs (miRNAs)—small non-coding RNAs of 20-22 nucleotides long [5–7]—as
well as the most recently acknowledged long non-coding RNAs (lncRNAs). LncRNAs are
non-protein coding transcripts greater than 200 nucleotides in length and lacking of extended
open reading frames [8–10]. As broadly suggested by several works [11–31], lncRNAs critically
participate in transcriptional and post-transcriptional regulation, though the biological func-
tions of the majority of them largely remain to be defined yet. Recent studies have shown that
some lncRNAs may have a role linked to their secondary structure [32–40], whose specific
substructures can function as guide or scaffold by binding chromatin-modifying protein com-
plexes [34, 37, 41, 42]. Although lncRNAs have low sequence conservation [43, 44], increasing
evidence indicates that also their primary structure (i.e. nucleotides sequence) could be instru-
mental for their implication in a wide variety of processes, including competition for miRNA
binding [30, 45–61].
Competing endogenous RNAs (ceRNAs), also known as miRNA “decoy” or miRNA
“sponges”, are RNA transcripts that compete for the binding to the same miRNA via the base-
pairing with miRNA recognition/response elements (MREs) [62–70], subsequently enabling
the reduction of the amount of miRNAs available to target messenger RNAs (mRNAs). Such a
mechanism of regulation of miRNA activity was firstly discovered in plants and called “target
mimicry” process [71].
The first experimental evidence of lncRNAs acting as miRNA decoys modulating the dere-
pression of miRNA targets has been found in wide variety of human cancers and specifically
concerns the functioning of pseudogenes (i.e. copies of real genes that originate from duplica-
tions or retro-transpositions) as competitors of their ancestral genes for miRNA binding [72].
They are not translated into functional proteins because their coding potential is corrupted by
premature stop codons, deletions/insertions and frameshift mutations. Nevertheless, nucleo-
tide sequences contained within pseudogenes are well preserved, suggesting that selective pres-
sure to maintain these genetic elements exists, and that they may indeed have an important
cellular role [72]. Moreover, pseudogenes are almost as numerous as coding genes and repre-
sent a significant proportion of the transcriptome [73]. They are perfect endogenous competi-
tors of their ancestral genes, since they retain many of the miRNA binding sites.
LncRNAs functioning as ceRNAs can be also observed in: mouse and human myoblasts,
where the large intergenic non-coding RNA (lincRNA) called linc-MD1 controls muscle
differentiation by targeting miR-133 and miR-135 to regulate the expression of MAML1
and MEF2C [74]; human embryonic stem cells, where linc-RoR competes with the tran-
scription factors NANOG, OCT4, SOX2 for binding to miR-145 regulating cell pluripotency
and self-renewing [75]; human thyroid cancer, where the thyroid-specific lncRNA PTCSC3
targets miR-574-5p [76]; human embryonic kidney 293 (HEK293) cells, where the lncRNA
H19 modulates the let-7 miRNAs family availability causing precocious muscle differentia-
tion [77].
Most recently, also the new-appreciate circular RNAs (circRNAs) appear to exert ceRNA
activity [70, 78–80]. They are a class of non-coding RNAs derived mostly from a non-canoni-
cal form of alternative splicing, whereby the exon ends are joined to form a continuous loop
[81–84]. In particular, the exonic circRNA CDR1 relieves the activity of miR-7 on its target
impairing midbrain development in mammals [85] and the testis-specific cirRNA Sry serves
as a miR-138 sponge [80].
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In our previous work [86], we developed a purely data-driven approach focused on the
identification of lncRNAs acting as new putative ceRNAs in a large set of tumour and
matched-normal samples (i.e. tissues that are adjacent to the tumour and taken from the same
patient) of breast invasive carcinoma available from The Cancer Genome Atlas (TCGA) [87,
88]. By applying a multivariate statistical analysis refined by the requirement of a seed match
enrichment, we built a network of miRNA-mediated sponge interactions (MMI-networks) in
both physiological and pathological states and compared the two obtained MMI-networks.
We found a marked rewiring in the ceRNA program between normal and pathological breast
tissues. At the heart of this phenomenon is the lncRNA PVT1 that serves as miRNA sponge in
normal tissues, but not in cancer. Moreover, it revealed, in normal MMI-network, a net bind-
ing preference towards the miR-200 family, which it antagonizes to regulate the expression of
hundreds of mRNAs known to be related to the cancer development and progression (e.g.
GATA3, CDH1, TP53, TP63, TP73, RUNX1, and RUNX3).
PVT1 is a large intergenic non-coding RNA that appears to be strongly conserved between
mouse and human [89–94]. The PVT1 gene [95] spans across a genome interval of over 300 kb
(i.e. bases 128806779–129113499 within the February 2009 human genome build GRCh37/
hg19) on the forward strand of chromosome 8 [96]. Moreover, PVT1 lies in a recognized can-
cer risk locus that it shares with MYC and shows highly complex gene architecture. Indeed, its
locus gives rise to over 20 different variants of the lncRNA according to the Ensembl annota-
tions of the human genome (release 75) and also produces a cluster of six annotated micro-
RNAs (i.e. miR-1204, miR-1205, miR-1206, miR-1207-5p, miR-1207-3p, and miR-1208) [96–
101]. The last years have been the scene of increasing advancements in studying PVT1 role in
tumour cells [28, 96, 102–107] and its overexpression appears as a frequent event in a wide
variety of cancers [98, 103, 104, 108, 109]. In addition to a putative ceRNA activity, interesting
ways of functioning of PVT1 have been suggested, such as the regulation of the protein stabil-
ity of the well-known MYC oncogene through its secondary structure [99, 110–112].
The miR-200 family consists of five members: miR-200a, miR-200b, miR-200c, miR-141
and miR-429. On the basis of the similarities of their seed sequences (i.e. 6 nucleotides at posi-
tions 2-7 from the miRNA 5’-end [113]), the miR-200 family members can be clustered into
two groups only differing for one nucleotide in the seed sequence: miR-200a/141 (AACACU)
and miR-200b/200c/429 (AAUACU) [114, 115]. The miR-200 family is one of the most widely
studied for its crucial role in cancer initiation, metastasis, diagnosis, and treatment. A large
number of studies showed that the down-regulation of the miR-200 family members appears
to promote the epithelial-mesenchymal transition, proving their suppressive effects on cancer
cell proliferation, migration, and invasion [115–118]. However, Park et al. [119] experimen-
tally demonstrated how the down-regulation of all members of the miR-200 family would
result in mesenchymal cell lines, while a their up-regulation would appear characteristic of an
epithelial phenotype.
In the dataset we analysed in [86], all members of the miR-200 family appear to be highly
up-regulated in cancer tissues (from 4- to 8- folds) and this up-regulation is counteracted by a
similar, even if not comparable, overexpression of PVT1 that in cancer tissues appears to
increase of about two folds. This observation could in principle warrant the annihilation of the
PVT1 sponge activity noted in cancer dataset. In fact, Salmena et al. [63] suggested that the
breakdown of the ceRNA activity could be due to a titration mechanism, i.e. large changes in
the ceRNA expression levels that either overcome, or relieve, the miRNA repression on com-
peting ceRNAs; similarly, large changes in the miRNA expression allow miRNAs to escape the
recruitment accomplished by ceRNAs.
Here, we are interested to analyse the specific conditions required for a ceRNA landscape to
occur, betting on the titration mechanism as the main culprit. In particular, inspiring by our
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amazing results of [86] and by the growing interest of the scientific community in the onco-
genic role of the lncRNA PVT1, we focused on its activity as sponge modulator of the activity
of the miR-200 family members on their targets and on the withdrawal of its decoy service in
breast cancer tissues.
Materials and methods
Algorithm for identifying ceRNA-ceRNA interactions
The pipeline of the algorithm for searching putative ceRNAs and for building the MMI-net-
work (Fig 1) in breast invasive carcinoma was presented in our previous work [86] and encom-
passed the following four steps: i. data collection and processing; ii. statistical analysis; iii. seed
match analysis; iv. network building.
1. Data collection and processing
Collections of tumour and normal expression data from high-throughput RNA- and
miRNA-sequencing of breast invasive carcinoma were downloaded from the TCGA data
portal [87, 88]. High-throughput sequencing data for both RNAs and miRNAs correspond
to level 3 data (i.e. normalized expression data) given in terms of FPKM (i.e. fragments per
kilobase of exon per million fragments mapped). The analysis was restricted to 72
Fig 1. Sensitivity correlation and normal MMI-network. (A) Left: heat-map representing the sensitivity correlation, given in the Eq 1, for
the top-correlated pairs (N = 87398) of mRNAs and lncRNAs (rows), previously identified in [86], in normal breast samples versus each
miRNA (columns) that was expressed in the same tissues. Light vertical stripes point to a little pool of miRNAs that are responsible for the
high correlation between all the top-correlated mRNA/lncRNA pairs. Colour key: red to blue scale corresponds to low to high sensitivity
correlation. Right: the distribution of the Pearson correlations between mRNA and lncRNAs expression profiles. The pairs that are
highlighted in red correspond to the top-correlated mRNA/lncRNA pairs: Pearson correlation values exceeding the 99th percentile of the
overall correlation distribution (i.e. ρ > 0.7 in normal samples). (B) The normal MMI-network (1738 nodes and 32375 edges) built in [86]
starting from the expression data of normal breast tissues. Nodes in this network represent both mRNAs and lncRNAs; edges represent
miRNAs that are mediating their interactions. Each pair of linked nodes fulfils two requirements: i. sensitivity correlation >0.3 and ii. one or
more shared MREs, for each miRNA linking them. Colours correspond to different miRNAs.
doi:10.1371/journal.pone.0171661.g001
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individuals for which the complete sets of tumour and matched-normal profiles—for both
short and long RNA-seq data—were available. Entries with more than the 10% of missing
values were filtered out; coding versus non-coding RNAs based on Entrez gene identifiers
and human annotation obtained from NCBI [120] were separated. The analysis was limited
to those mRNAs with an available 3’ untranslated region (3’UTR) sequence at least equal to
500 nt in the curated UTRdb database [121]. All together, a total of 10492 mRNAs, 311
miRNAs, and 833 lncRNAs were analysed in [86].
2. Statistical analysis
The top-correlated mRNA/lncRNA pairs in normal and cancer data sets were selected by
setting in both cases the correlation threshold to the 99th percentile of the corresponding
overall correlation distribution (Fig 1A). Then, two regression models were built up: i. the
expression profile of the mRNA is the dependent variable X and the expression profile of
the miRNA is the explanatory variable Z; ii. the expression profile of the lncRNA is the
dependent variable Y and the expression profile of the miRNA is the explanatory variable Z.
The X and Y variables correspond to the top-correlated mRNA/lncRNA pairs.
To infer the role of Z in mediating X − Y correlation, the partial correlation was computed:
rXY jZ ¼
rXY   rXZrZYffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1   r2XZ
p ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1   r2ZY
p
where ρX, Y is the Pearson correlation. Then, the sensitivity correlation S was defined as:
S ¼ rXY   rXY jZ ð1Þ
The XYZ triplets with S> 0.3, corresponding to a drop of about the 30% in the correlation
between XY when Z is removed, were selected. Finally, these triplets were restricted to
those enriched in binding sites of the shared miRNA (hypergeometric test p-value <0.01).
3. Seed match analysis
The minimal pairing requirement to predict a miRNA target recognition is a perfect match
to positions 2 to 7 (6-mer miRNA seed) at the 5’-end of the mature miRNA sequence [122].
The miRNA seed sequences were obtained by mapping TCGA miRNA identifiers to miR-
Base [123]. Complementary DNA (cDNA) sequences (i.e. without introns) for lncRNAs
were obtained querying the Ensembl [124] data portal through its R/Bioconductor [125]
interface provided by the package biomaRt and by using Entrez gene identifiers [126]. For
each 3’UTR sequence included in the dataset analysed in [86], all the occurrences matching
the reverse-complement of the 6-mer seed for the miRNAs analysed were recorded. Simi-
larly, for each lncRNA included the dataset analysed in [86] all the occurrences of short
sites matching the reverse-complement of a miRNA seed in the entire transcript sequence
were stored. The lists of coding and non-coding RNA identifiers used to retrieve corre-
sponding sequences were built based on gene annotations obtained from the NCBI [120].
4. Network building
The MMI-network both in normal and cancer tissues was built by integrating the results of
statistical analysis and seed match analysis. Nodes in the networks represent mRNAs and
lncRNAs with highly correlated expression profiles while edges represent miRNAs mediat-
ing their interactions. Concretely, linked nodes are required to meet three conditions: i.
matching high values of the Pearson correlation between their expression profiles (ρ> 0.7);
ii. matching high values of the sensitivity correlation (S> 0.3); iii. sharing binding sites for
miRNAs (6-mer miRNA seed match).
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Raw data retrieval and processing
Data collection. Mapped read data (bam files) for the 72 patients (for which the complete
sets of tumour and matched-normal profiles—for both short and long RNA-seq data—were
available) analysed in [86] were downloaded from the TCGA [87] via controlled access (i.e. by
using the TCGA dedicated software “gtdownload” to query via controlled access the
restricted-access data repository). For each patient the relative two bam files corresponding to
the breast tumour and normal sample are used as input for the Cufflinks software [127] in
order to assemble transcripts and to estimate the relative abundances of these transcripts. As
output formats the Cufflinks suite used FPKM tracking format. Then, we used Cuffmerge (a
software included in Cufflinks) in order to merge together the 72 Cufflinks assemblies.
The PVT1 locus assembled by Cufflinks was compared with genome annotations for the
same locus provided by Ensembl (release Homo sapiens GRCh37) by running the Cuffcom-
pare utility and by careful inspection of the above assemblies and annotations on the UCSC
genome browser.
Targeted reassembly of the PVT1 locus were performed using the Trinity software [128]
with default parameters and digital normalization of the reads. To highlight possible differ-
ences between the healthy and tumour samples three independent assemblies were carried
out, by using: a) all the reads mapping to the PVT1 locus from both cancer and normal tissue,
b) only cancer reads, c) only reads from normal tissues. A UCSC genome browser track show-
ing the main results of these analyses is available through this link: https://genome.ucsc.edu/
cgi-bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=pantaleoM&hgS_
otherUserSessionName=hg19_pone_S16_46501
While the overall agreement between the Trinity and Cufflinks assemblies is good, and
both methods concur in recovering all of the PVT1 Refseq exons, we notice that some of exons
predicted by Cufflinks are not supported by any of Trinity assemblies, and likely constitute
false positives. Importantly the most prevalent isoforms reconstructed by Trinity are highly
similar if not completely identical to the two most expressed PVT1 isoforms TCONS_147426
and TCONS_147501 predicted by Cufflinks, suggesting that these discrepancies in the assem-
bly are not likely to play a major effect on isoforms abundance estimation. A differential alter-
native exon usage analysis (S1 Fig), performed by comparing the normalized reads counts
distributions on the Refseq PVT1 exons, shows a striking pattern supporting the up-regulation
of all the exons downstream of exon 5 in the tumour samples. This observation is highly con-
sistent with our hypothesis that the up-regulation of PVT1 in tumour samples is mostly due to
the up-regulation of isoforms of the gene devoid of the key exons exerting the sponge activity
on miR-200 family members.
Statistical analysis. The PVT1 locus—assembled by the reference-based RNA-Seq tran-
scriptome assembler Cufflinks using TCGA data of breast invasive carcinoma—is composed
of 91 different isoforms (S2 Fig and S1 File). The FPKM normal and cancer data of these iso-
forms (S1 Table) were subjected to a pre-processing and filtering operation in order to reduce
data noise and to select only the ones that show a statistically significant fold-changes between
cancer and normal tissues (p-values of the Student’s t-test <0.05). Thus, the number of the
PVT1 isoforms to analyse was trimmed to 17 isoforms.
Data classification. In order to classify the PVT1 isoforms on the basis of the FPKM data,
we used the Principal Component Analysis (PCA) [129, 130]. PCA operates on a n-by-p data
matrix X, whose rows correspond to the n observations and columns to the p variables. The
representation of X in the principal component (PC) space is known as matrix of the principal
component scores (S2 Table), whose rows correspond to observations and columns to the
principal components (PCs). The transformation matrix from the old to the new coordinate
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system is known as matrix of factors (S2 Table), whose rows correspond to variables and col-
umns to components. In this study, the original variables are the 72 patients and the observa-
tions are the PVT1 isoforms’ variations (i.e. the difference of the expression levels of the PVT1
isoforms between cancer and normal tissues).
Results and discussion
Inspiring by our previous study presented in [86], in this manuscript we have investigated the
specific conditions required for a ceRNA interaction network to occur. In particular, we thor-
oughly studied the intriguing phenomenon of the breakdown of the PVT1 functioning as
sponge of the miR-200 family members in the breast invasive carcinoma by analysing the
expression data of its multiple isoforms (S1 Table). The starting point of the present analysis,
which complements the results obtained in [86], is represented by the investigation of the sen-
sitivity correlation behaviour (Fig 1A), formerly inspected in [86] and whose mathematical
expression is reported in Eq 1. This enables measuring the contribution of miRNAs in mediat-
ing the ceRNAs cross-talk and provides compelling clues on the nature of the ceRNA interac-
tions, i.e. indirect (direct) interaction meaning that the ceRNAs communication is (is not)
arbitrated by one or more microRNAs. As already mentioned in [86], in physiological condi-
tions the value of the sensitivity correlation is almost zero, i.e. the Pearson correlation is equal
to the partial correlation, leading to the expected conclusion that, in normal breast tissues, the
majority of the miRNAs is not arbitrating the cross-talk between long non-coding RNAs and
coding RNAs. Thus, the observed high correlations between the expression profiles of the top-
correlated lncRNA/mRNA pairs could be presumably ascribable to a common transcriptional
regulatory mechanism, rather than to a post-transcriptional regulation program orchestrated
by shared miRNAs. Nevertheless, a small pool of miRNAs appears as responsible of the vertical
light stripes that unexpectedly stand out from the prevailing red colour of the background of
Fig 1A. Hence, these miRNAs can be reasonably envisaged as the mediators of the interactions
between all the highly correlated pairs in the normal breast samples. Among them, there are all
members of the miR-200 family, whose importance in breast cancer is well-known and is
related to the epithelial-mesenchymal transition. This pattern completely disappears in cancer
[86] to give way to the activation of a different ceRNA landscape. This “on/off” switch from
normal to cancer, and vice-versa, leads to the inference of a marked rewiring in the ceRNA
program between normal and pathological breast tissue that confers an interesting character
to ceRNAs as potential oncosuppressive, or oncogenic, protagonists in cancer.
Using the sensitivity correlation and the results of the seed match analysis, summarised in
Materials and Methods section, the MMI-network was built in both the physiological and
pathological condition of human breast cancer dataset analysed in [86]. Nodes of these net-
work are lncRNAs and mRNAs that are competing for miRNA binding and links are the
“bone of contention” miRNAs (Fig 1B). The lncRNA PVT1 with its 2169 edges represents the
first hub (i.e. the node with the largest number of links or the highest degree in the network) in
the normal-MMI-network. It is connected to 753 different mRNAs (* 50% of total mRNAs in
the network) and the miR-200 family members are arbitrating over the 80% of these interac-
tions (Fig 2A). Moreover, PVT1 has as nearest neighbours some of the well-known cancer
genes (Fig 2B) and is connected to 753 different mRNAs representing more than the 50% of all
the mRNAs in the whole normal MMI-network (Fig 2C).
By analysing the expression profiles of PVT1, obtained from the dataset studied in [86],
over all the patients, we found that it is up-regulated in breast cancer tissues both as mean
value (Fig 3A) and individually on each patient, regardless of the breast cancer subtypes (Fig
3B). This up-regulation is counteracted by a similarly, but even more significant,
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overexpression of the miR-200 family members (see Fig 3A and 3C for the representative case
of the miR-200b). The question, then, arises: if PVT1 and the miR-200 family are both up-reg-
ulated in cancer, why PVT1 stops working as sponge in cancer?
The analysis of the PVT1 genomic locus showed the existence of multiple isoforms (Fig 4
and S2 Fig) representing all the possible configurations: hosting the binding site for some (e.g.
Iso6 or Iso7 in Fig 4) or all members of the miR-200 family (e.g. Iso1 in Fig 4); missing the
binding site (e.g. Iso11 and Iso12 in Fig 4). This consideration together with the observed syn-
chronised up-regulation of the PVT1 gene and the miR-200 family members encouraged us to
hypothesize different scenarios that could be in principle compatible with the ceasing of the
PVT1 sponge activity in breast cancer tissues. From one hand, the absence in two PVT1 iso-
forms of the exon where the MREs for the all members of the miR-200 family reside could lead
to support the hypothesis of a preferential expression in cancer tissues of these two isoforms,
thus justifying the lack of the miRNA/target interaction with a consequent breakdown of the
PVT1 ceRNA activity (i.e. the exon skipping mechanism). From the other hand, the observa-
tion of a simultaneous up-regulation of the PVT1 gene and the miR-200 family members
could lead to support the alternative hypothesis of different relative concentrations between
each isoform and the miR-200 family members. According to that, a substantial decrease in
cancer tissues of the relative variation of the isoform harbouring the binding site for one or
more members of the miR-200 family could be due to a huge increase of the miR-200 family
associated with a moderate growth in cancer of the expression levels of this PVT1 isoform.
This situation, completely different from what occurs in normal tissues where the miRNA/tar-
get concentrations are comparable, could give reason of the PVT1 cease-activity as ceRNA in
cancer (i.e. a titration mechanism).
Fig 2. PVT1: the first hub of the normal MMI-network. (A) The percentage of the miRNAs sponged by PVT1 with respect to all of its links.
More than the 80% corresponds to the miR-200 family members. (B) Some nearest neighbours of PVT1 that are well-known cancer genes
as the members of the p53 family or the members of the RUNX family, as well as E-cadherin. (C) The sponge interactions sub-network of
PVT1. It consists of 2169 edges and 753 nodes, more than the 50% of all the mRNAs in the whole normal MMI-network.
doi:10.1371/journal.pone.0171661.g002
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To shed light on which of the two hypothesised mechanisms lies the origin of the PVT1
stoppage as sponge, we looked at the PVT1 abundance in terms of its isoforms and we found
that in both normal (Fig 5A and S3 Table) and cancer tissues (Fig 5B and S3 Table) only two
isoforms represent the biggest slices: the first largest slice—which corresponds to the 50%
(48%) of the PVT1 total abundance in normal (cancer) breast samples—represents the isoform
missing the binding site for the miR-200 family (TCONS_147501); the second largest slice—
which corresponds to the 15% (17%) of the PVT1 total abundance in normal (cancer) breast
samples—represents the isoform hosting the binding site for the miR-200b/200c/429 cluster
(TCONS_147426). Overall, both in normal and cancer tissues the two isoforms
TCONS_147501 and TCONS_147426 represent about the 65% of the total abundance of
PVT1 (S3 Table). Moreover, PVT1 resulted up-regulated also in terms of its total isoforms
abundance (Fig 5C), confirming the result obtained at gene level (Fig 3A).
The observation that both the isoforms, with and without the exons where the MREs of the
miR-200 family memebrs reside, resulted expressed in both cancer and normal breast tissues
Fig 3. PVT1 and miR-200b expression levels in human breast cancer tissues. The main actors of the normal MMI-network are the miR-
200 family members and the long non-coding PVT1. Both of them appear to be up-regulated in breast cancer tissues with respect to normal
breast tissues. (A) The mean and the standard deviation for the long non-coding PVT1 and for the miR-200b, one member of the miR-200
family, in normal (red boxes) and cancer samples (black boxes). In figure the p-values resulting from the statistical hypothesis Student’s t-
test are reported. (B-C) Level 3 (i.e. normalized expression data) IlluminaHiSeq expression data of PVT1 and the miR-200b for all patients
given in terms of FPKM (i.e. fragments per kilobase of exon per million fragments mapped). Red boxes correspond to normal tissues while
black boxes correspond to cancer tissues.
doi:10.1371/journal.pone.0171661.g003
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undermine the truthfulness of the hypothesis rested on the exon skipping mechanism and cor-
roborates the proposal based on the relative concentrations of the PVT1 isoforms and the
miR-200 family members.
Thus, in order to sift through the validity of a titration mechanism, we performed the prin-
cipal component analysis using the feature abundance levels of all the PVT1 isoforms across
samples (S1 Table). The aim of PCA is to determine the principle axes of the abundance varia-
tion and to separate the isoforms according to this feature. This is achieved through a reduc-
tion of the space dimensionality that transforms a high-dimensional dataset—where the
dimension of the space is equal to the linear independent variables (i.e. patients)—into a
smaller-dimensional subspace—where the dimension of the space is equal to number of PCs
that are able to explain the first 100% of the cumulative distribution of the explained variance
of the data. The first step of this analysis is to draw a new axis representing the direction of
maximum variation through the data (the first PC). Next, another axis is added orthogonal to
the first and positioned to represent the next highest variation through the data (the second
PC), and so on.
We found that two PCs are able to explain more than the 80% of the variance of the data
(Fig 6A and S2 Table). In order to understand the meaning of these two PCs, we drew the
score plot (Fig 6B and S2 Table) and found that the first PC is able to separate the contribution
of the isoform missing the binding site for any members of the miR-200 family from the oth-
ers, while the second PC is able to separate the contribution of the isoform hosting the binding
site for the miR-200b/200c/429 cluster from the others.
Fig 4. Sketch of the PVT1 locus in humans. Model of PVT1 genomic locus as reconstructed by Cufflinks (S1 File) spans across a genome
interval of over 300 kb (i.e. bases 128,806,789-129,113,603 within the February 2009 human genome build GRCh37/hg19) on the forward
strand of chromosome 8. The large PVT1 locus gives rise to 91 different variants (S2 Fig) according to raw RNA-seq data of TCGA for breast
invasive carcinoma. The isoform names correspond to an increasing symbolic numbering and not to the actual nomenclature of the PVT1
variants. Lines represent introns and boxes (red and grey) represent exons. Red boxes correspond to the binding sites for the miR-200
family members. Note that some isoforms lack such binding sites (e.g. Iso11 and Iso12).
doi:10.1371/journal.pone.0171661.g004
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This suggests the following argument of plausibility of the PCA analysis results: the first PC,
which explain by alone about the 60% of the total variance of the analysed data (S2 Table), cor-
responds to the variation of the isoform that, missing the binding site, does not interact with
the miR-200 family; while the second PC, explaining by alone about the 20% of the total vari-
ance of the analysed data (S2 Table), represents the variation of the isoform that, hosting the
binding site for the miR-200b/200c/429 cluster, could be act as competitors of the targets of
these miRNAs. Overall the variation between cancer and normal tissues of these two isoforms
accounts for more than the 80% of the variance of the data (Fig 6A and S2 Table).
Studying the variation of each PVT1 isoform between normal and cancer breast tissues
with respect to the variation of TCONS_147501, the results of PCA seems to be confirmed (Fig
7 and S4 Table): the isoform harbouring the binding site for the miR-200b/200c/429 cluster
and the isoform missing the binding site for any member of the miR-200 family, are the only
isoforms that change (Fig 7A).
Thus, we considered only these two isoforms (S2 File) and evaluated the ratio between the
abundance of each one with respect to one representative member of the miR-200b/200c/429
cluster (i.e. miR-200b) in both normal and cancer tissues. For the TCONS_147501 isoform
(missing the binding site) this ratio does not change between normal and breast cancer tissues,
while in the case of the TCONS_147426 isoform (harbouring the binding site) this ratio shows
a drastic decrease from normal to cancer tissues (Fig 7B). We speculate that the
TCONS_147426 isoform acts as sponge regulator of the miR-200b in normal breast tissues,
while the sponge mechanism is broken down in cancer tissues because this isoform shows a
much lower concentration with respect to the miR-200b (Fig 8A). Informally speaking, such a
Fig 5. PVT1 isoforms in normal and cancer breast tissues. The PVT1 abundance in terms of its isoforms in normal (A) and cancer
tissues (B) of breast invasive carcinoma. The percentage are calculated with respect to the total abundance of PVT1 in normal and cancer
tissues (S3 Table). In both panels, the red slice corresponds to the isoform (TCONS_147426) with seed match for the miR-200b/200c/429
cluster and the blue slice corresponds to the isoform (TCONS_147501) lacking the binding site for any member of the miR-200 family. (C)
The average of PVT1 abundance on all the isoforms both in normal and cancer tissues.
doi:10.1371/journal.pone.0171661.g005
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sponge mechanism works as a real sponge: before saturation the sponge can hold more water,
beyond saturation—there is too much water—the sponge can not hold more (Fig 8B).
So, our analysis supports the hypothesis that the “on/off” switch from normal to cancer
state of the PVT1 sponge activity is mostly due to the variation of the relative concentration of
PVT1 isoform hosting the binding site for the miR-200b/200c/429 cluster.
Conclusion
Starting from the results presented in [86]—where we analysed the complex interactions
among mRNAs, long non-coding RNAs, and microRNAs in breast invasive carcinoma—here
we investigated the mechanism underlying the marked rewiring of the sponge program
between normal and cancer tissues. In particular, the analysis of the normal miRNA-mediated
interactions network, built in [86], pointed out how the main actors of this rewiring were
PVT1 and the miR-200 family members. Specifically, PVT1 emerged as a putative ceRNA
modulating the activity of all members of the miR-200 family on their target mRNAs, which
are well-known to be drastically involved in breast cancer morphogenesis and development.
Interestingly, such a sponge mechanism resulted completely abolished in cancer tissues,
although both PVT1 and the miR-200 family members appeared up-regulated in the patholog-
ical condition. Thus, processing the raw data from TCGA, which provided the abundance of
the multiple isoforms generated by the PVT1 genomic locus, we tried to grasp the rational
behind the turning off of this sponge mechanism. In particular, the principal component
Fig 6. Principal component analysis. (A) The percent variability explained by each principal component (S2 Table). It is a type of chart,
called Pareto chart, that contains both bars and a line graph, where individual values are represented in descending order by bars, and the
line represents the cumulative total value. In particular, the y-axis represents the percentage of the data variance explained by each principal
component, whereas the x-axis represents the principal components that are able to explain the first 100% of the cumulative distribution.
The PCA is performed using the variations of all the isoforms between normal and cancer tissues. Two components explain more than the
80% of the variance of the data. (B) The scatter plot (score plot) of the projection of the original data (i.e. the variations of all the isoforms
between normal and cancer tissues) onto the first two PCs; the x-axis contains the first PC while the y-axis contains the second PC (S2
Table). In this plot, it is possible to group isoforms in three classes: the isoform missing the binding site for the miR-200 family members (blue
isoform, TCONS_147501), the isoform with the seed match for the miR-200b/200c/429 cluster (red isoform, TCONS_147426), and all the
others. The first PC, which explains about the 60% of the variance in the original data, is able to separate the variation of the blue isoform
from the others; the second PC, which explains about the 20% of the variance in the original data, is able to separate the variation of the red
isoform from the others.
doi:10.1371/journal.pone.0171661.g006
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analysis suggested that the variations between cancer and normal breast tissues of all PVT1 iso-
forms can be explained by only two principal components: one corresponding to the isoform
harbouring the binding site for the miR-200b/200c/429 cluster and the other one representing
the isoform missing the binding site for any member of the miR-200 family members. More-
over, comparing the relative expression levels of these two isoforms both in normal and cancer
tissues with respect to the ones of the one representative member of the miR-200b/200c/429
cluster (i.e. miR-200b), we found a drastic drop, in the pathological condition, in the relative
concentration of the PVT1 isoform hosting the binding site for the miR-200b. The drastic
change observed in the sponge program, which is suggestive of a marked ceRNA rewiring that
Fig 7. PVT1 isoforms variation. (A) The variations between cancer and normal tissues of all the PVT1 isoforms with respect to the
variation of the blue isoform lacking the binding site for the miR-200 family members (S4 Table). The red and blue isoforms are the only
isoforms that change. (B) The ratio between the abundance of the blue and red isoform with respect to the miR-200b in both normal (striped
rectangle) and cancer tissues (full boxes). The p-values resulting from the statistical hypothesis Student’s t-test are reported. The ratio
between the blue isoform and the miR-200b does not change, while the ratio between the red isoform and the miR-200b shows a drastic fall
in cancer tissues.
doi:10.1371/journal.pone.0171661.g007
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characterizes the cancer state, could support the testable hypothesis of a titration mechanism
regarding the two main isoforms of PVT1 and the miR-200 family members.
Supporting information
S1 Fig. Differential alternative PVT1 usage analysis. This figure shows the results of a differ-
ential alternative exon usage analysis, performed by comparing the normalized reads counts
distributions on the Refseq PVT1 exons. It shows a striking pattern supporting the up-regula-
tion of all the exons downstream of exon 5 in the tumour samples. This observation is highly
consistent with our hypothesis that the up-regulation of PVT1 in tumour samples is mostly
Fig 8. Sponge mechanism. (A) The ratio between the abundance of the red isoform (harbouring the binding site for the miR-200b/200c/429
cluster) over the abundance of the miR-200b in both normal (striped rectangle) and cancer tissues (full boxes). (B) Our hypothesis for the
breakdown of the sponge mechanism in breast cancer orchestrated by PVT1 and the miR-200 family members. We speculate that in the
normal tissues only the red isoform of PVT1 gene acts as sponge regulator of the miR-200 family members. In cancer tissues it stops
working as sponge since its concentration is much lower than the concentration of the miR-200 family members (here is reported only the
case of miR-200b). It is like in the case of a real sponge: before saturation the sponge can hold more water, beyond saturation—there is too
much water—the sponge can’t hold more.
doi:10.1371/journal.pone.0171661.g008
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due to the up-regulation of isoforms of the gene devoid of the key exons exerting the sponge
activity on miR-200 family members.
(PNG)
S2 Fig. Visualisation of PVT1 genomic locus in human. This figure shows the 91 PVT1 iso-
forms (i.e. bases 128,806,789-129,113,603 within the February 2009 human genome build
GRCh37/hg19) visualised within the UCSC Genome browser (https://genome.ucsc.edu/) and
assembled by the reference-based RNA-Seq transcriptome assembler Cufflinks by using the
TCGA breast invasive carcinoma dataset.
(PNG)
S1 File. Reconstruction of PVT1 genomic locus in human. This file contains PVT1 gene
annotations in GTF (Gene Transfer Format) format provided by the reference-based RNA-Seq
transcriptome assembler Cufflinks. This file is a simple tab-delimited text file for describing
genomic features and it can be uploaded to a genome browser such as the UCSC Genome
browser (https://genome.ucsc.edu/) in order to obtain the S2 Fig.
(GTF)
S2 File. Sequences of two PVT1 isoforms. This file contains the full genome sequences (in
FASTA format) of the two PVT1 isoforms that mostly change between normal and cancer tis-
sues: TCONS_147501 (missing the binding site for miR-200 family members) and
TCONS_147426 (harbouring the binding site for the miR-200b/200c/429 cluster).
(FA)
S1 Table. PVT1 isoforms expression levels. This table reports the FPKM values of PVT1 iso-
forms across normal and cancer breast tissues in separate and accordingly named sheets.
(XLSX)
S2 Table. Principal Component Analysis. This table reports the results of the principal com-
ponent analysis, in separate and accordingly named sheets: first sheet) the eigenvalues of the
covariance matrix of the n-by-p data matrix X, whose rows correspond to observations (i.e. iso-
forms’ variations that are the difference of the expression levels of the PVT1 isoforms between
cancer and normal tissues) and columns to variables (i.e. patients), the variance accounted for
by each component, and the cumulative function; second sheet) the matrix of the principal
component scores, whose rows correspond to observations and columns to components; third
sheet) the matrix of factors, whose rows correspond to variables and columns to components.
(XLSX)
S3 Table. PVT1 isoform abundance. This table reports the percentage of PVT1 abundance,
showed in Fig 5, in terms of its isoforms both in normal and cancer tissues of TCGA breast
invasive carcinoma.
(XLSX)
S4 Table. PVT1 isoforms variation. This table reports the variations between cancer and nor-
mal tissues of the expression levels of all the PVT1 isoforms with respect to the variation of the
TCONS_147501 isoform lacking the binding site for the miR-200 family members, showed in
Fig 7A.
(XLSX)
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